Trial Number



Esophageal Cancer

Participant Age Range

18 years and older

Participant Gender


Enrolling Participants



A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

This is a Phase 3, randomized, double-blind, placebo-controlled multi-site study ofpembrolizumab in combination with dCRT versus placebo in combination with dCRT in participants with histologically or cytologically confirmed diagnosis of cTX N+ M0 or cT2-T4a NX M0 ESCC (as defined by AJCC 8th edition), GEJC, EAC, or histologically or cytologically confirmed diagnosis of cTX N+ M1 cervical or upper thoracic esophageal carcinoma with supraclavicular lymph node metastases only and who are candidates for dCRT.


Related Clinical Trials

Click on the category you are interested in.

Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.